Profile data is unavailable for this security.
About the company
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.
- Revenue in USD (TTM)35.00m
- Net income in USD-121.25m
- Incorporated2019
- Employees157.00
- LocationIteos Therapeutics Inc321 Arsenal StreetBldg 312, Floor 3, Suite 301WATERTOWN 02472United StatesUSA
- Phone+1 (857) 204-4583
- Fax+1 (302) 655-5049
- Websitehttps://www.iteostherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rezolute Inc | 0.00 | -69.31m | 284.50m | 59.00 | -- | 2.40 | -- | -- | -1.27 | -1.27 | 0.00 | 2.05 | 0.00 | -- | -- | 0.00 | -58.64 | -50.36 | -62.66 | -53.25 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.19 | -- | -- | -- |
| Atea Pharmaceuticals Inc | 0.00 | -174.01m | 284.64m | 75.00 | -- | 0.6208 | -- | -- | -2.07 | -2.07 | 0.00 | 5.43 | 0.00 | -- | -- | 0.00 | -31.67 | -5.90 | -32.99 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Aldeyra Therapeutics Inc | 0.00 | -44.80m | 288.82m | 10.00 | -- | 3.39 | -- | -- | -0.7538 | -0.7538 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -33.86 | -36.79 | -39.67 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1522 | -- | -- | -- | 39.47 | -- | -- | -- |
| Absci Corp | 4.21m | -97.67m | 290.70m | 155.00 | -- | 1.45 | -- | 69.10 | -0.9357 | -0.9357 | 0.0402 | 1.76 | 0.0178 | -- | 3.66 | 27,141.94 | -41.42 | -- | -46.85 | -- | -- | -- | -2,321.56 | -- | -- | -157.35 | 0.0269 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Vanda Pharmaceuticals Inc. | 190.86m | -16.39m | 296.79m | 203.00 | -- | 0.5484 | -- | 1.56 | -0.2824 | -0.2824 | 3.29 | 9.28 | 0.2967 | 9.30 | 5.30 | 940,187.20 | -2.55 | 6.61 | -2.95 | 7.62 | 93.62 | 90.55 | -8.59 | 15.18 | 4.84 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Q32 Bio Inc | 0.00 | -49.66m | 299.04m | 42.00 | -- | 16.29 | -- | -- | -7.44 | -7.44 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -27.86 | -34.98 | -33.25 | -37.92 | -- | -- | -- | -971.76 | -- | -- | 0.4079 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| C4 Therapeutics Inc | 33.67m | -105.50m | 300.00m | 145.00 | -- | 1.24 | -- | 8.91 | -1.70 | -1.70 | 0.5217 | 3.44 | 0.095 | -- | 6.21 | 232,193.10 | -29.76 | -25.91 | -33.20 | -29.45 | -- | -- | -313.35 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Nautilus Biotechnology Inc | 0.00 | -70.21m | 301.35m | 161.00 | -- | 1.35 | -- | -- | -0.561 | -0.561 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -24.29 | -- | -25.05 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| Neurogene Inc | 925.00k | -71.13m | 301.55m | 91.00 | -- | 1.92 | -- | 326.00 | -4.49 | -4.49 | 0.0582 | 10.56 | 0.0073 | -- | -- | 10,164.83 | -56.07 | -32.70 | -61.14 | -34.73 | -- | -- | -7,689.95 | -- | -- | -- | 0.0007 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
| Compass Pathways PLC (ADR) | 0.00 | -144.32m | 301.74m | 186.00 | -- | 1.56 | -- | -- | -2.19 | -2.19 | 0.00 | 2.82 | 0.00 | -- | -- | 0.00 | -52.83 | -40.85 | -57.18 | -44.48 | -- | -- | -- | -- | -- | -- | 0.1337 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| iTeos Therapeutics Inc | 35.00m | -121.25m | 303.86m | 157.00 | -- | 0.4811 | -- | 8.68 | -3.15 | -3.15 | 0.9064 | 17.29 | 0.05 | -- | 1.43 | 222,929.90 | -17.31 | 5.84 | -18.16 | 7.02 | -- | -- | -346.44 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
| Voyager Therapeutics Inc | 163.78m | 25.88m | 308.39m | 162.00 | 9.62 | 0.9338 | 9.97 | 1.88 | 0.5876 | 0.5876 | 2.94 | 6.06 | 0.4545 | -- | 14.29 | 1,011,012.00 | 7.18 | 0.6378 | 8.42 | 0.8203 | -- | -- | 15.80 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Lexicon Pharmaceuticals Inc | 5.23m | -216.39m | 312.11m | 285.00 | -- | 1.75 | -- | 59.69 | -0.7513 | -0.7513 | 0.018 | 0.4938 | 0.0175 | 0.6955 | 3.25 | 18,347.37 | -72.42 | -24.41 | -81.77 | -29.01 | 93.54 | 98.49 | -4,138.33 | -84.92 | 7.43 | -12.32 | 0.3588 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| SAGE Therapeutics Inc | 106.40m | -337.59m | 316.27m | 487.00 | -- | 0.5731 | -- | 2.97 | -5.58 | -5.58 | 1.76 | 9.02 | 0.1354 | -- | 5.24 | 218,478.40 | -42.95 | -21.88 | -48.97 | -23.30 | 91.75 | 99.63 | -317.29 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| Design Therapeutics Inc | 0.00 | -47.78m | 318.21m | 54.00 | -- | 1.26 | -- | -- | -0.8465 | -0.8465 | 0.00 | 4.46 | 0.00 | -- | -- | 0.00 | -17.02 | -- | -17.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
Data as of Nov 25 2024. Currency figures normalised to Iteos Therapeutics Inc's reporting currency: US Dollar USD
50.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Sep 2024 | 3.18m | 8.72% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 2.61m | 7.16% |
| Tang Capital Management LLCas of 30 Sep 2024 | 2.41m | 6.59% |
| BVF Partners LPas of 14 Nov 2024 | 2.33m | 6.37% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.62m | 4.43% |
| EcoR1 Capital, LLCas of 30 Sep 2024 | 1.61m | 4.41% |
| 683 Capital Management LLCas of 30 Sep 2024 | 1.57m | 4.30% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 1.18m | 3.22% |
| Citadel Advisors LLCas of 30 Sep 2024 | 1.08m | 2.95% |
| Vestal Point Capital LPas of 30 Sep 2024 | 1.03m | 2.81% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
